LDS/Medical Tests/Hunter Syndrome (IDS) Gene Mutation Analysis

Hunter Syndrome (IDS) Gene Mutation Analysis

Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS). The IDS gene encodes for enzyme called iduronate 2-sulfatase (I2S), which is essential for the breakdown of large sugar molecules called glycosaminoglycans (GAGs). Specifically, I2S removes a chemical group known as a sulfate from a molecule called sulfated alpha-L-iduronic acid, which is present in two GAGs called heparan sulfate and dermatan sulfate. I2S is located in lysosomes, compartments within cells that digest and recycle different types of molecules.

This deficiency leads to progressive accumulation of heparan and dermatan sulfate within cellular lysosomes. The age of onset, disease severity, and rate of progression vary significantly among affected males. Death may occur in individuals with early progressive disease due to the CNS involvement (manifest primarily by progressive cognitive deterioration), progressive airway disease, and cardiac disease.

Individuals with slowly progressive MPS II can live with normal intelligence since the CNS is minimally affected. Additional findings in both forms of MPS II include: short stature, macrocephaly with or without communicating hydrocephalus, macroglossia, hoarse voice, conductive and sensorineural hearing loss, hepatosplenomegaly, dysostosis multiplex, spinal stenosis, and carpal tunnel syndrome. The diagnosis of MPS II is based on measuring urine levels of glycosaminoglycans (GAGs) and may be confirmed by measuring I2S activity and/or analyzing for I2S gene mutations.

  • Diagnostic confirmation of mucopolysaccharidosis type II
  • Carrier screening for family members at risk
  • For the prenatal diagnosis in at-risk pregnancies
  • For pre-implantation genetic diagnosis of MPS II
Any mutation or pathogenic variant in IDS gene is consistent with a diagnosis of mucopolysaccharidosis type II (MPS-II), or Hunter syndrome. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

No reportable variants were identified

Sequence analysis by next generation sequencing or bi-directional sequencing. IDS gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood (EDTA), skin biopsy, cultured cells.

Stability (blood)

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Urinary glycosaminoglycans (GAGs - Dermatan sulfate, heparan sulfate), iduronate 2-sulfatase enzyme activity, comprehensive mucopolysaccharidosis (MPS) gene mutation panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Genet Med. 2011;13: 95-101. [PMID: 21150784]
  • Pediatrics. 2008;121: e377-86. [PMID: 18245410]
  • Genet Med. 2008 Jul;10(7):508-16. [PMID: 18580692]
  • Pediatr Neurol. 2005;32: 270-2. [PMID: 15797184]
  • GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from http://www.ncbi.nlm.nih.gov/books/NBK1274/
  • Genetics Home Reference. Available: https://ghr.nlm.nih.gov/condition/mucopolysaccharidosis-type-ii#